ArticleQatar medical journal2022

Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population.

Fateen Ata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.